Q-omics provides the consensus-scored STPG3 profile across patient tissues and cancer cell-line models. STPG3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, STPG3 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, STPG3 RNA expression shows 17,300 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, COAD, and UVM as cancer lineages where STPG3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STPG3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STPG3 survival associations across molecular data types. STPG3 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STPG3 RNA expression–survival associations across cancer types. High STPG3 expression shows unfavorable associations in COAD, MESO and SCLC, but favorable associations in LUAD, PAAD and HNSC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify LUAD as the clearest survival context for STPG3 RNA expression.
This table summarizes STPG3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for STPG3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STPG3 shows lower tumor expression in KICH and higher tumor expression in COAD, HNSC, LIHC, STAD and ESCA. The COAD box plot shows higher STPG3 RNA expression in tumor versus normal tissue (log2 FC = +0.414, t-test p < 0.001).
This table shows molecular features associated with STPG3 in patient tissues and cancer cell lines. In patient samples, STPG3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, STPG3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in SKIN and SOFT_TISSUE.
